The nonstaff members of IAS–USA Drug Resistance Mutations Group are volunteers and are not compensated for their role in overseeing the program. Listed below are the IAS–USA Drug Resistance Mutations Group members and their financial relationships with commercial interests within the past 12 months from the date of disclosure.


Vincent Calvez, MD, PhD
Hopital Pitie-Salpetriere
Paris, France

Dr Calvez has served as an advisor or consultant to and has received research grants from Bristol-Myers Squibb, Johnson and Johnson, ViiV Healthcare, and Gilead Sciences, Inc and is a founder of SkinDermic Pharma. (Updated 07/20/18)

Huldrych F. Günthard, MD
Professor of Infectious Diseases
University Hospital Zurich
Zurich, Switzerland

Dr Günthard has served as a consultant to Merck, Sandoz, Teva, and Gilead Sciences, Inc and received research grants from the Swiss National Science Foundation, Systems.X (HIV.X), Swiss HIV Cohort Study, the Yvonne Jacob Foundation, and Gilead Sciences, Inc. (Updated 07/24/18)

Victoria A. Johnson, MD
Professor of Medicine and Microbiology
University of Alabama at Birmingham
Birmingham, Alabama

Dr Johnson has no relevant financial affiliations to disclose. (Updated 01/30/17)

Roger Paredes, MD, PhD
HIV Unit and IrsiCaixa AIDS Research Institute
Hospital Universitari Germans Trias I Pujol
Badalona, Spain

Dr Paredes has received research grants from ViiV Healthcare and Merck. (Updated 07/20/18)

Deenan Pillay, MD, PhD
Professor of Virology
University College London
United Kingdom
Director of the Africa Centre for Health and Population Studies
University of KwaZulu Natal
Mtubatuba, South Africa

Dr Pillay has no relevant financial affiliations to disclose. (Updated 07/20/18)

Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California San Diego
San Diego, California

Dr Richman has been a consultant to Antiva Biosciences; Gilead Sciences, Inc; and Viriome, Inc. (Updated 12/06/18)

Robert W. Shafer, MD
Assistant Professor
Stanford University
Stanford, California

Dr Shafer has received grants from Merck, Janssen Pharmaceuticals, Vela Diagnostics, Bristol-Myers Squibb, and Gilead Sciences, Inc and personal fees from Abbott Diagnostics and ViiV Healthcare. (Updated 07/20/18)

Annemarie M. Wensing, MD, PhD
University Medical Center Utrecht
Utrecht, The Netherlands

Dr Wensing has served on advisory boards for CLJI Worldwide, ViiV Healthcare,  Merck, Janssen Pharmaceuticals, and Gilead Sciences, Inc; received grants from Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences, Inc; and received support from Virology Education (conference organizer). (Updated 07/20/18)